Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials

Clinical and Experimental Allergy

Volumn 47, Issue 1, 2017, Pages 129-138

  Cabon, Y ^a   Molinari, N ^a,b   Marin, G ^a   Vachier, I ^a   Gamez, A S ^a   Chanez, P ^c   Bourdin, A ^a,b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF MONTPELLIER   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENRALIZUMAB; INTERLEUKIN 5; MEPOLIZUMAB; PLACEBO; RESLIZUMAB; ANTIASTHMATIC AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ASTHMA; ASTHMA CONTROL QUESTIONNAIRE 5; COMPARATIVE STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG SAFETY; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; HUMAN; META ANALYSIS; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE ASSESSMENT; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; LUNG FUNCTION TEST; METABOLISM; SEVERITY OF ILLNESS INDEX;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; BIOMARKERS; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-5; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85006386654     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12853     Document Type: Review

References (33)

1. Reddel HK, Bateman ED, Becker A et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J 2015; 46:622–39.
2. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167:199–204.
3. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161:1720–45.
4. Bousquet J, Chanez P, Lacoste JY et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323:1033–9.
5. Lötvall J, Akdis CA, Bacharier LB et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127:355–60.
6. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18:716–25.
7. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol 2006; 24:147–74.
8. Bourdin A, Humbert M, Chanez P. Immunologic therapeutic interventions in asthma: impact on natural history. Clin Chest Med 2012; 33:585–97.
9. Humbert M, Beasley R, Ayres J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309–16.
10. Hanania NA, Wenzel S, Rosén K et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187:804–11.
11. Woodruff PG, Modrek B, Choy DF et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180:388–95.
12. Castro M, Mathur S, Hargreave F et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184:1125–32.
13. Castro M, Wenzel SE, Bleecker ER et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014; 2:879–90.
14. Laviolette M, Gossage DL, Gauvreau G et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013; 132:1086–1096.e5.
15. Castro M, Zangrilli J, Wechsler ME et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3:355–66.
16. Bel EH, Wenzel SE, Thompson PJ et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371:1189–97.
17. Ortega HG, Liu MC, Pavord ID et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371:1198–207.
18. Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380:651–9.
19. Flood-Page P, Swenson C, Faiferman I et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176:1062–71.
20. Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973–84.
21. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. Disponible sur: http://handbook.cochrane.org/ [cité 6 oct 2016].
22. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London, UK:National Institute for Health and Care Excellence (NICE)
23. Jansen JP, Fleurence R, Devine B et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: Part 1. Value Health 2011; 14:417–28.
24. Lunn D, Spiegelhalter D, Thomas A, Best N. The BUGS project: evolution, critique and future directions. Stat Med 2009; 28:3049–67.
25. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14:902–7.
26. Liu Y, Zhang S, Li D, Jiang S. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS ONE 2013; 8:e59872.
27. Powell C, Milan SJ, Dwan K, Bax L, Walters N. Mepolizumab versus placebo for asthma. Cochrane Database Syst Rev 2015; 7:CD010834.
28. Keating GM. Mepolizumab: first global approval. Drugs 2015; 75:2163–9.
29. Ortega H, Chupp G, Bardin P et al. The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. Eur Respir J 2014; 44:239–41.
30. Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365:1088–98.
31. Wenzel S, Ford L, Pearlman D et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368:2455–66.
32. Gauvreau GM, O'Byrne PM, Boulet L-P et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014; 370:2102–10.
33. Krug N, Hohlfeld JM, Kirsten A-M et al. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med 2015; 372:1987–95.